Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Shah

Showing results (281-290 of 296) with videos related to

Pageof 30
Sort By:
European Urology Oncology|November 18, 2021
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial CancerOmar Alhalabi, Yueting Zhu, Ameer Hamza, et al.
Scientific Reports|September 1, 2018
OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancersPaloma Del C Monroig-Bosque, Maitri Y Shah, Xiao Fu, et al.
Cancers|December 10, 2021
Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal StudiesDaniel D Shapiro, Melinda Soeung, Luigi Perelli, et al.
Der Nervenarzt|May 28, 2021
[Telemedicine in stroke-pertinent to stroke care in Germany]J Barlinn, S Winzer, H Worthmann, et al.
The New England Journal of Medicine|March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
The Lancet. Oncology|September 7, 2025
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trialChad Tang, Alexander D Sherry, Aaron Seo, et al.
The Lancet. Gastroenterology & Hepatology|March 16, 2025
Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trialBruno C Odisio, Jessica Albuquerque, Yuan-Mao Lin, et al.
Nature Communications|July 4, 2024
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapySang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Communications|April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapySang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Pageof 30

Showing results (281-290 of 296) with videos related to

Sort By:
Pageof 30
European Urology Oncology|November 18, 2021
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial CancerOmar Alhalabi, Yueting Zhu, Ameer Hamza, et al.
Scientific Reports|September 1, 2018
OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancersPaloma Del C Monroig-Bosque, Maitri Y Shah, Xiao Fu, et al.
Cancers|December 10, 2021
Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal StudiesDaniel D Shapiro, Melinda Soeung, Luigi Perelli, et al.
Der Nervenarzt|May 28, 2021
[Telemedicine in stroke-pertinent to stroke care in Germany]J Barlinn, S Winzer, H Worthmann, et al.
The New England Journal of Medicine|March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
The Lancet. Oncology|September 7, 2025
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trialChad Tang, Alexander D Sherry, Aaron Seo, et al.
The Lancet. Gastroenterology & Hepatology|March 16, 2025
Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trialBruno C Odisio, Jessica Albuquerque, Yuan-Mao Lin, et al.
Nature Communications|July 4, 2024
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapySang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Communications|April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapySang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Pageof 30